# Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea

> **NCT01057147** · PHASE2 · COMPLETED · sponsor: **Kubota Vision Inc.** · enrollment: 116 (actual)

## Conditions studied

- Keratoconjunctivitis Sicca
- Dry Eye

## Interventions

- **DRUG:** rebamipide 2% ophthalmic suspension
- **DRUG:** placebo eye drops

## Key facts

- **NCT ID:** NCT01057147
- **Lead sponsor:** Kubota Vision Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-01
- **Final completion:** 2011-02
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2012-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01057147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01057147, "Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01057147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*